Eiger eager to send COVID-19 drug to FDA after hospitalizations

        Eiger BioPharmaceuticals' drug, licensed from Bristol Myers Squibb in 2016, halved the risk of hospitalizations or emergency room visits lasting longer than six hours in patients with COVID-19, including those with the omicron variant, in a phase 3 trial. With the 50% reduction, which means the drug met its primary goal , Eiger is headed to the FDA "as soon as possible" for emergency use authorization, executives said in an interview with Fierce Biotech. The FDA is first priority, then the European Medicines Agency and other countries to follow.

        At present, the epidemic prevention war is still severe. Laboratories in various countries are developing drugs and reagents to treat the COVID-19 . During the experiment, it is crucial to keep the experimental environment clean and sterile. Pecybio’s biological consumable products are all manufactured in a 100000 cleanroom which gives the experimental results a safe and scientific guarantee. We hope that laboratories and people around the world will take action to win this war against epidemics.

       The following are some of our star products, if you are interested, you can contact us to order!